Loading NURECA price...
Peers are the listed companies in the exchange's own industry group: Medical Equipment & Supplies. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 21 Jul 2026), sales rose 18.0% from a year earlier to Rs 40.3 cr and profit rose 277.4% to Rs 3.1 cr.
- Operating margin rose from -13.5% in FY23 to 0.1% in FY26.
- Reported a loss in FY24.
- Return on equity stayed under 10% from FY24 to FY26 (highest 1.1%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 18 results, the share rose on 5 and fell on 13, and moved by 3% or more on 10.
Q1 FY27: results filed 21 Jul 2026. The share went from its close on 20 Jul 2026 to its close on 22 Jul 2026 +10.15%.
Of every Rs 100 of sales in FY26, Rs 100 went on running costs, Rs 1.4 on depreciation, Rs 0.9 on interest and Rs 2.0 on tax; Rs 1.4 was left as profit.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | -56.4% | -17.4% | 19.4% | 34.0% |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | 21.7% | -13.5% | -11.1% | -6.9% | 0.1% |
| Net marginProfit after everything, per Rs 100 of sales. | 17.6% | -7.4% | -2.0% | 0.7% | 1.4% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | -4.2% | -0.9% | 0.4% | 1.1% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | -5.2% | -1.1% | 1.3% | 3.4% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | - | 0.02x | 0.00x | 0.01x | 0.00x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | 88.1x | -20.4x | -4.0x | 2.1x | 4.8x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 196 Cr of assets. Its owners funded 92% of that and borrowings 0%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 3 Cr, spent Rs 7 Cr on plant and equipment, and cash fell by Rs 2 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| POLYMED Poly Medicure Limited | 14,631 cr | 46.5x | 4.7x | 9.9% | 13.2% | 0.11 | 15.7% | +30.3% | 0.24% |
| FISCHER Fischer Medical Ventures Limited | 1,767 cr | 10.6x | 4.6x | 7.7% | 12.7% | 0.19 | 8.1% | +249.4% | 0.02% |
| TARSONS Tarsons Products Limited | 1,587 cr | 142.7x | 2.5x | 1.8% | 4.8% | 0.60 | 2.5% | +20.7% | 0.00% |
| LAXMIDENTL Laxmi Dental Limited | 945 cr | 30.5x | 3.9x | 12.7% | 11.5% | 0.00 | 10.8% | +13.9% | 0.00% |
| FABTECH Fabtech Technologies Limited | 543 cr | 8.8x | 1.3x | 11.6% | 11.6% | 0.10 | 11.7% | +10.3% | 0.00% |
| QMSMEDI QMS Medical Allied Services Limited | 334 cr | - | - | - | - | - | - | - | - |
| NURECA Nureca Limited | 296 cr | 72.1x | 1.6x | 2.4% | 3.4% | 0.00 | 2.8% | +18.0% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from 21.7% to 0.1% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2022 paid Rs 3.00 per share, about Rs 967 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.